Northern Trust
CMPX icon

Northern Trust’s Compass Therapeutics CMPX Stock Holding History

Northern Trust’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.5M Buy
1,140,914
+92,356
+9% +$273K ﹤0.01% 3003
2026
Q1 		$5.55M Buy
1,048,558
+75,623
+8% +$436K ﹤0.01% 2401
2025
Q4 		$5.22M Buy
972,935
+111,000
+13% +$513K ﹤0.01% 2448
2025
Q3 		$3.02M Buy
861,935
+127,241
+17% +$402K ﹤0.01% 2803
2025
Q2 		$1.91M Sell
734,694
-68,444
-9% -$141K ﹤0.01% 3011
2025
Q1 		$1.53M Buy
803,138
+1,913
+0.2% +$5.09K ﹤0.01% 3068
2024
Q4 		$1.16M Sell
801,225
-43,164
-5% -$71.7K ﹤0.01% 3327
2024
Q3 		$1.55M Buy
844,389
+96,825
+13% +$121K ﹤0.01% 3146
2024
Q2 		$748K Sell
747,564
-19,347
-3% -$28.3K ﹤0.01% 3359
2024
Q1 		$1.52M Buy
766,911
+7,178
+0.9% +$12.4K ﹤0.01% 3105
2023
Q4 		$1.19M Sell
759,733
-65,381
-8% -$113K ﹤0.01% 3251
2023
Q3 		$1.63M Buy
825,114
+55,249
+7% +$137K ﹤0.01% 3052
2023
Q2 		$2.45M Buy
769,865
+584,562
+315% +$1.84M ﹤0.01% 2895
2023
Q1 		$606K Buy
185,303
+28,220
+18% +$111K ﹤0.01% 3384
2022
Q4 		$790K Buy
157,083
+69,716
+80% +$278K ﹤0.01% 3348
2022
Q3 		$199K Buy
+87,367
New +$242K ﹤0.01% 3876

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust's CMPX Position: Q2 2026 in Review

Northern Trust increased its Compass Therapeutics (CMPX) stake by 8.8% in Q2 2026, buying an estimated $273K and bringing the position to 1,140,914 shares worth $2.5M. The position accounts for ﹤0.01% of the portfolio, ranked #3003.

Northern Trust first reported a position in CMPX in Q3 2022 and has held it in 16 quarters since. The position peaked at $5.55M in Q1 2026. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Northern Trust held 1,140,914 shares of Compass Therapeutics worth $2.5M as of Q2 2026.
  • Northern Trust bought 92,356 Compass Therapeutics shares in Q2 2026, an estimated $273K.
  • Compass Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #3003 holding.
  • Northern Trust first reported a position in Compass Therapeutics in Q3 2022 and has held it in 16 quarters since.
  • Northern Trust's Compass Therapeutics position peaked at $5.55M in Q1 2026.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.